厄洛替尼联合贝伐珠单抗一线治疗EGFR敏感突变阳性晚期非小细胞肺癌的临床观察  

Clinical Observation of Erlotinib Combined with Bevacizumab in First-line Treatment of EGFR Sensitive Mutation Positive Advanced Non-small Cell Lung Cancer

作　　者：郝冠磊 尚双霞 HAO Guanlei;SHANG Shuangxia(General Hospital of Pingmei Shenma Group,Pingdingshan,467000)

机构地区：[1]平煤神马医疗集团总医院,467000

出　　处：《实用癌症杂志》2024年第10期1680-1683,共4页The Practical Journal of Cancer

摘　　要：目的观察厄洛替尼联合贝伐珠单抗一线治疗表皮生长因子受体(EGFR)敏感突变阳性晚期非小细胞肺癌的临床效果。方法采用前瞻性随机对照研究,选择EGFR敏感突变阳性晚期非小细胞肺癌患者作为研究对象。采用随机数字表法将患者分为对照组与观察组,对照组采用厄洛替尼治疗,观察组采用厄洛替尼联合贝伐珠单抗治疗。比较2组患者临床疗效、血清肿瘤标志物水平[癌胚抗原(CEA)、细胞角蛋白21-1片段(CYFRA21-1)、血管内皮生长因子(VEGF)]、免疫功能[白细胞分化抗原3(CD3)、白细胞分化抗原4(CD4)、白细胞分化抗原8(CD8)]以及用药不良反应情况。结果治疗3个月后,观察组患者客观缓解率(ORR)、疾病控制率(DCR)均高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组血清CEA、CYFRA21-1、VEGF水平低于对照组,差异有统计学意义(P<0.05);观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组,差异有统计学意义(P<0.05)。2组患者治疗不良反应发生率比较,差异无统计学意义(P>0.05)。结论厄洛替尼联合贝伐珠单抗一线治疗EGFR敏感突变阳性晚期非小细胞肺癌可以有效提高临床疗效,改善患者免疫功能。Objective To observe the clinical efficacy of erlotinib combined with bevacizumab in first-line treatment of advanced non-small cell lung cancer with positive epidermal growth factor receptor(EGFR)sensitive mutations.Methods A prospective randomized controlled study was conducted,selected advanced non-small cell lung cancer patients with positive EGFR sensitive mutations as the study subjects.The patients were divided into the control group and the observation group using a random number table method.The control group received treatment with erlotinib,while the observation group received treatment with erlotinib combined with bevacizumab.The clinical efficacy,serum tumor marker levels[carcinoembryonic antigen(CEA),cytokeratin 21-1 fragment(CYFRA21-1),vascular endothelial growth factor(VEGF)],immune function[leukocyte differentiation antigen 3(CD3),leukocyte differentiation antigen 4(CD4),leukocyte differentiation antigen 8(CD8)],and adverse drug reactions were compared between 2 groups of patients.Results After 3 months of treatment,the objective response rate(ORR)and disease control rate(DCR)of the observation group were higher than those of the control group,with a statistical significant difference(P<0.05).After treatment,the serum CEA,CYFRA21-1,and VEGF levels in the observation group were lower than those in the control group,with a statistical significant difference(P<0.05).The CD3^(+),CD4^(+),CD4^(+)/CD8^(+)levels in the observation group were higher than those in the control group,while CD8^(+)levels were lower than those in the control group,with a statistical significant difference(P<0.05).There was no statistical significant difference in the incidence of adverse reactions between the 2 groups of patients(P>0.05).Conclusion The combination of erlotinib and bevacizumab first-line treatment can effectively improve the clinical efficacy and immune function of EGFR sensitive mutation positive advanced non-small cell lung cancer patients.

关 键 词：非小细胞肺癌 晚期 表皮生长因子受体敏感突变阳性 厄洛替尼 贝伐珠单抗 一线治疗 

分 类 号：R734.2[医药卫生—肿瘤]